Found 25 articles for: "Crisaborole"
Novel Clinical Applications of Topical Ruxolitinib: A Case Series
March 2024 | Volume 23 | Issue 3 | Case Reports | 188 | Copyright © March 2024
Topical ruxolitinib, a potent Janus kinase (JAK) inhibitor, has shown significant efficacy in treating inflammatory skin conditions. While its use has already been established in atopic dermatiti...
Read MoreINDIVIDUAL ARTICLE: Pediatric Atopic Dermatitis Patient Cases Integrating Ceramides-Containing Cleansers and Moisturizers into Prescription Treatment and Maintenance Approaches
December 2023 | Volume 22 | Issue 12 | Supplement Individual Articles | SF389716s3 | Copyright © December 2023
Introduction: Atopic dermatitis (AD) is a common, chronic recurrent disorder typically starting in infancy and early childhood and associated with pruritus and genetic predisposi...
Read MoreINDIVIDUAL ARTICLE: An Algorithm for the Management of Atopic Dermatitis in People With Skin of Color
August 2023 | Volume 22 | Issue 8 | Supplement Individual Articles | SF386361s3 | Copyright © August 2023
Background: Variations in the epidemiology, clinical presentation, and disease course in skin of color (SOC) atopic dermatitis (AD) patients have been reported that may impact tr...
Read MoreDo Atopic Dermatitis Patient-Reported Outcomes Correlate With Validated Investigator Global Assessment? Insights From TARGET-AD Registry
April 2023 | Volume 22 | Issue 4 | Original Article | 344 | Copyright © April 2023
Background: Research examining associations between the clinician-reported validated Investigator Global Assessment for AD (vIGA-AD) and patient-reported disease burden is sparse...
Read MoreThe Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study
February 2023 | Volume 22 | Issue 2 | Original Article | 139 | Copyright © February 2023
Background: Patients with atopic dermatitis (AD) need safe and effective topical treatments.
Objective: To assess safety and efficacy of roflumilast cream in pa...
Read MoreAtopic Dermatitis Polypharmacy and Out-Of-Pocket Healthcare Expenses
February 2023 | Volume 22 | Issue 2 | Original Article | 154 | Copyright © February 2023
Background: Atopic dermatitis (AD) out-of-pocket (OOP) expenses are substantial and impact household finances. Prescription polypharmacy and its association with OOP expenses in AD is...
Read MoreMeasuring and Improving Adherence to Crisaborole 2% Ointment in Patients With Atopic Dermatitis
October 2022 | Volume 21 | Issue 10 | Original Article | 1043 | Copyright © October 2022
Background: Atopic dermatitis (AD) is an inflammatory skin condition with dry, scaly, and intensely itchy skin. Treatment failure is the result of poor adherence.
Object...
Read MorePhase 2 Trial of Topical Thykamine in Adults With Mild to Moderate Atopic Dermatitis
October 2022 | Volume 21 | Issue 10 | Original Article | 1091 | Copyright © October 2022
Background: Atopic dermatitis is a common skin disorder for which there remains an unmet need for topical pharmacotherapies that are safe and effective. This phase 2 study assessed th...
Read MoreInsights in Skin of Color Patients With Atopic Dermatitis and the Role of Skincare in Improving Outcomes
May 2022 | Volume 21 | Issue 5 | Original Article | 462 | Copyright © May 2022
Background: Research on the role of race and ethnicity in the pathophysiology of atopic dermatitis (AD) is limited. Variations in the epidemiology, clinical presentation, and disease ...
Read MoreThe Heterogeneity of Atopic Dermatitis
February 2022 | Volume 21 | Issue 2 | Original Article | 172 | Copyright © February 2022
Background: Recent advances were made in characterizing the clinical heterogeneity of atopic dermatitis (AD).
Objective: To review the clinical domains contribu...
Read MoreTopical Agents Currently in Phase II or Phase III Trials for Atopic Dermatitis
October 2020 | Volume 19 | Issue 10 | Original Article | 956 | Copyright © October 2020
Mild to moderate atopic dermatitis (AD) occurs frequently in children and adults and is usually managed through the use of pharmacologic treatments, such as topical corticosteroids (TCS) and topical c...
Read MoreDevelopment and Evaluation of an Atopic Dermatitis Care Plan for Providers
October 2020 | Volume 19 | Issue 10 | Original Article | 950 | Copyright © October 2020
Background/Significance of problem: Atopic Dermatitis (AD) is a common, chronic, inflammatory dermatosis and skin disease that follows a relapsing pattern and requires a dynamic stepw...
Read MoreRoflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study
August 2020 | Volume 19 | Issue 8 | Original Article | 734 | Copyright © August 2020
Background: Roflumilast cream (ARQ-151) is a highly potent, selective phosphodiesterase-4 inhibitor in development for once-daily topical treatment of chronic plaque psoriasis.
...
Read MoreDemographics and Baseline Disease Characteristics of Early Responders to Crisaborole for Atopic Dermatitis
June 2020 | Volume 19 | Issue 6 | Original Article | 619 | Copyright © June 2020
Introduction: Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate atopic dermatitis (AD). This post hoc, pooled analysis id...
Read MoreExacerbation of Pediatric Periorificial Dermatitis: A Novel Adverse Reaction
April 2020 | Volume 19 | Issue 4 | Editorials | 428 | Copyright © April 2020
Topical Agents for the Treatment of Atopic Dermatitis
January 2020 | Volume 19 | Issue 1 | Editorials | 50 | Copyright © January 2020
Approval of the new topical phosphodiesterase 4 inhibitor crisaborole ointment, 2%, to treat mild-to-moderate atopic dermatitis (AD) warrants careful consideration of available efficacy and safety dat...
Read MoreManagement of Atopic Dermatitis
February 2019 | Volume 18 | Issue 2 | Supplement Individual Articles | 111 | Copyright © February 2019
Atopic Dermatitis (AD) is estimated to affect 15-20% of children and remains a major health consideration for pediatricians and dermatologists.1 Over the past three decades, studies have shown an incr...
Read MoreNavigating Targeted Therapeutics in Dermatology: Biologics and Small Molecules
December 2018 | Volume 17 | Issue 12 | Features | 1330 | Copyright © December 2018
Dermatology is entering an exciting era with new, targeted immune-modulating medications for treating a variety of dermatologic conditions including psoriasis, atopic dermatitis (AD), and hidradenitis...
Read MoreConsensus Recommendations on Adjunctive Topical Management of Atopic Dermatitis
October 2018 | Volume 17 | Issue 10 | Original Article | 1070 | Copyright © October 2018
Atopic dermatitis (AD) is well-recognized as a very common chronic and relapsing pruritic skin disorder affecting both children and adults worldwide. The adverse effects on the quality of life of affe...
Read MoreEconomic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis
July 2018 | Volume 17 | Issue 7 | Original Article | 750 | Copyright © July 2018
Background. Moderate-to-severe atopic dermatitis can be difficult and costly to treat. The long-term health and economic outcomes of a new therapy, dupilumab, have yet to be evaluated. We aimed to ide...
Read MoreMedia and other results for: "Crisaborole"
© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
